title: Pharmacometrics 2020.
abstract: This special issue of the Journal of Clinical Pharmacology is dedicated to pharmacometrics, covering topics related to methodological research, application to decisions, standardization, PhRMA survey, and growth strategy. Innovative methodological and technological advances in analyzing disease, drug, and trial data have equipped pharmacometricians with the know-how to influence high-level decisions, which in turn creates more pharmacometric opportunities. Pharmacometrics is revolutionizing drug development and regulatory decision making. To sustain the success and growth of this field, we need to up the ante. Strategic goals for pharmacometric groups in industry, regulatory agencies, and academia are proposed in this report. These goals should be of significance to all stakeholders who have a vested interest in drug development and therapeutics. The future of pharmacometrics depends on how well we all can deliver on the strategic goals.
authors.affiliation: Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. jogarao.gobburu@fda.hhs.gov
authors.forename: Jogarao V S
authors.initials: JV
authors.lastname: Gobburu
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods*; D003659:Decision Making, Organizational; D015195:Drug Design; D004345:Drug Industry / Q000379:methods / Q000458:organization & administration; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D012107:Research Design
chemical_list: D004364:Pharmaceutical Preparations